This spin-off from Asan Medical Center focuses on developing therapeutic and diagnostic agents for neurological diseases, with a particular emphasis on Alzheimer's disease. In 2016, the company completed its incorporation and business registration processes, establishing its presence in the market. It obtained certification as a corporate-affiliated research institute in 2017, solidifying its reputation as a research-driven organization. The company has also been recognized as a leading university start-up by the Ministry of SMEs and Startups. Through collaborations with Oscotech Co., Ltd. and partnerships with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., the company is jointly developing its projects. One of its notable developments is a novel tau antibody for the treatment of Alzheimer's disease.